SIED

Sied Biopharma is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the discovery and development of next-generation targeted protein degradation (TPD) therapies. The company leverages its proprietary molecular glue discovery platform to target "undruggable" proteins involved in cancer and other serious diseases. Sied's lead programs focus on hematological malignancies and solid tumors, utilizing small molecule degraders to achieve potent therapeutic effects. By combining structural biology with high-throughput screening, the company aims to expand the scope of TPD beyond traditional PROTACs. Its lead candidate, SD-91, is currently in Phase 1 clinical trials for advanced solid tumors. The company is backed by prominent investors including Sequoia China and 5Y Capital.